Cabaletta Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing financial and operational information as a late-stage clinical biotechnology company.

Key Highlights

  • Shares outstanding: As of October 30, 2026, the company had 215,720,392 shares of common stock, $0.00001 par value per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Key product candidate: The company disclosed it is conducting Phase 1/2 RESET clinical trials for resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201).
  • Manufacturing dependence: The company disclosed it is "highly dependent" on Lonza Houston Inc. and Cellares Corporation for current manufacturing needs for its clinical trials.
  • Continuing losses: The company stated it has "incurred significant losses since our inception" and anticipates it "will continue to incur significant losses for the foreseeable future."
  • Additional funding needed: The company disclosed it "will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales."

Cabaletta Bio's Q3 2026 Quarterly Disclosure: Clinical Programs and Key Risk Factors

Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company headquartered at 2929 Arch Street, Suite 600, Philadelphia, PA 19104, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies the company as a non-accelerated filer and smaller reporting company. As of October 30, 2026, 215,720,392 shares of common stock were outstanding, according to the filing.

The filing centers on the company's Phase 1/2 RESET clinical trials for rese-cel, its lead product candidate. The company disclosed reliance on two contract manufacturers, Lonza Houston Inc. and Cellares Corporation, for manufacturing needs supporting those trials. The filing noted that if "manufacturing capacity at any of these manufacturing partners is reduced or otherwise delayed or limited," it "could adversely impact the supply of product candidates for and enrollment in our trials." The company also disclosed that it is reliant on intellectual property licensed from Nanjing IASO Biotherapeutics Co., Ltd., and that termination of that license "would result in the loss of significant rights, which would have a material adverse effect on our business."

Among the material risks summarized in the filing, the company stated it has a limited operating history, has incurred significant losses since inception, and anticipates continuing to incur significant losses. It further disclosed a need to raise substantial additional funding prior to completing development of any product candidate or generating product revenue. The filing also noted forward-looking statements regarding the timing of clinical trial enrollment, data readouts, regulatory submissions, and the use of proceeds from at-the-market common stock offerings, all of which are subject to the company's cautionary language regarding known and unknown risks and uncertainties.

What Was Disclosed

Cabaletta Bio submitted its quarterly Form 10-Q for the period ended September 30, 2026, reporting 215,720,392 shares outstanding as of October 30, 2026, and disclosing ongoing Phase 1/2 clinical trials for rese-cel along with manufacturing reliance, licensing dependencies, and continued operating losses.